Executive Management Team
Chief Executive Officer
Ian Muir has 30 years’ experience in the pharmaceutical industry. With a PhD in Pharmaceutical Science, he has worked for GSK, Wyeth and Mayne Pharma in the UK, US and Australia. He then moved to the CDMO sector joining Catalent Pharma Services the global CDMO, where he held both technical and commercial roles, ultimately leading their global oral products division. He has experience operating as CEO at both Aesica Pharma and Famar. Most recently he has been a principal advisor at Results Healthcare in their M&A team and the lead for the contract manufacture team of the UK BEiS, Vaccine Task Force.
Soren Demin studied for his undergraduate degree in Sheffield before matriculating to the University of Cambridge for his postgraduate research in Biosensing, with a focus on the redox site of Glucose Oxidase & electrochemistry helping understanding of how biology can be interfaced with electronic components and its applicable in areas of bio-sensing, photovoltaics and organic computing.
He has worked for Tier 1 Investment bank, and a range of pharmaceutical companies in the Business Development function with a focus on; Licencing, M&A activities, growth strategy, organisational & change management for the last 10 years. He is a fellow of the Royal Society of Medicine and joined Porton Biopharma as the new Commercial Director in 2019. Whilst at Cambridge Soren was awarded the Future Leaders in Biotechnology prize, and was a multiple Cambridge blue.
Director of Production
Shane has a B. Sc. (Hons) degree in Biochemistry and over 20 years’ experience in the biopharmaceutical industry. He has held management positions in both Quality Control and Manufacturing divisions and has significant experience of regulatory inspections. Shane joined HPA/PHE as Deputy Head of Manufacturing in 2009 becoming Head of Manufacturing in 2012.
Prior to this, Shane spent 17 years at Therapeutic Antibodies UK Limited/Protherics UK Limited, comprising 9 years as Quality Control Manager and 7 years as Production Manager/Head of Manufacturing. In his role as Head of Manufacturing at Protherics, Shane also headed Technical Support and Process Development functions.
Director of Human Resources
Dr Nara Ringrose brings more than 35 years of experience in strategic and operational HR. She is a Chartered Fellow CIPD; Chartered Fellow CMI; Certified HR Practitioner, Certified HR Executive and has a PhD in geopolitics; BA(Hons) in economic, political and human geography.
Prior to joining PBL, Nara held a number of senior HR posts in the engineering; oil and gas; mining & exploration; education and manufacturing sectors where she was responsible for HR strategies and advised on best people practices and how organisations add value to clients and investors through strategic and operational HR practices.
Director of Quality
Burleigh has more than 30 years experience across a broad range of senior roles in Quality Assurance, GMP Manufacturing, Operational Excellence, Validation and Process Development/Technology Transfer in the Bio/Pharmaceutical sector. He is passionate advocate for Operational Excellence and is an accomplished Lean Six Sigma practitioner having gained his Black Belt on the Pfizer US certified programme.
Prior to joining PBL Burleigh has worked in both big pharma as Senior Quality Director with GSK Vaccines leading the Global Product Quality team, Director of Quality Management/Continuous Improvement Lead with Pfizer as well as in start-up biopharmaceutical companies most recently, leading the Quality function at Midatech Pharma. Burleigh has an M.Sc in Biochemical & Chemical Engineering from the University College London and a B.Sc (Hons) in Biochemistry from Manchester University. He also has a Master in Business Administration (MBA) from the Open University, and is an active member of both the International Society of Pharmaceutical Engineers and Parenteral Drug Association.
Director of Finance
Sue has over 25 years of experience in a variety of senior finance roles in the private sector for both Global ‘Blue Chip’ corporations and privately-owned companies in the technology and services industries. Sue is a qualified Certified Accountant, with an audit background, having commenced her career in an audit and accountancy practice.
Director of Regulatory Affairs & Pharmacovigilance
Liz Madichie has extensive operational, strategic and leadership experience in global regulatory, pharmacovigilance and product development strategies, across the bio-pharmaceutical and CRO industry. An active industry advocate and thought leader, Liz proactively pursues opportunities to advance the regulatory paradigm.
Liz is a Chartered Chemist, Fellow Royal Society of Chemistry (RSC); Fellow Chartered Management Institute (CMI); Member, and former Board Member (2018-2019), of The Organisation of Professionals in Regulatory Affairs (TOPRA). She holds a PhD in Analytical Chemistry, MSc in Analytical Science and BSc (Hons) in Chemistry with Analytical Chemistry and Toxicology from the University of Hull, and diplomas in management from the CMI and Open University.
After obtaining a degree in Economics & Statistics, Nigel qualified as an accountant. He has extensive experience working in a variety of senior finance roles in the private sector, in both the service and manufacturing industries; this includes periods with LRV Industries, Warner Lambert (Pfizer) and Coopervision, both in the UK and overseas.
Director of Engineering
Mike has 20 years’ experience in Commissioning and Qualification, technical roles and project management with major Pharmaceutical and Service provider companies, where he has established a track record in the delivery of Engineering projects, Quality Systems & Assurance, and Process & Equipment Validation.
Director of Logistics & Project Management
Roger Price has over 30 years’ experience in the life science industry including the last 10 years within a pharmaceutical manufacturing based organisation. A graduate chemist he has previously held positions in QC, manufacturing, development and research with GE Life Sciences.